Indoco Remedies Share Price in Focus; Reports 7.4% Revenue Growth in Q2FY27

Indoco Remedies closed the September quarter with consolidated revenue from operations of ₹506.92 crore, against ₹471.83 crore in the same quarter of FY2025-26. The result was announced on October 27, 2026. 

Net profit for the quarter was ₹19.47 crore, compared with a loss of ₹9.24 crore a year earlier. The company reported a profit before tax of ₹24.19 crore.  

However, before exceptional items, it recorded a loss before tax of ₹22.95 crore. Exceptional items contributed ₹37.14 crore to the reported result. 

Gain from Property Sale 

The exceptional items included ₹36.63 crore from the sale of the company's property in Andheri East, Mumbai. Indoco also received ₹51 lakh for granting rights to use its trademarks. 

For the first half of FY2026-27, consolidated net profit stood at ₹84.92 crore, compared with a loss of ₹45.55 crore in the corresponding period last year. 

Revenue and EBITDA 

Consolidated revenue from operations increased 7.4% year on year to ₹506.92 crore in Q2FY27. For the six months ended 30 September 2026, revenue rose to ₹973.14 crore from ₹902.70 crore, an increase of 7.8%. 

EBITDA for the quarter was ₹46.4 crore, compared with ₹43.1 crore in the year-ago period. The EBITDA margin edged up to 9.2% from 9.1%. For the first half, EBITDA increased to ₹87.5 crore from ₹60.6 crore, while the margin rose to 9% from 6.7%. 

Segment Performance  

Indoco's regulated international formulations business recorded 21.1% growth during Q2FY27. For the first half, the active pharmaceutical ingredients business grew 22%, while Allied Services reported growth of 27.4%. 

Read More: Tata Communications Share Price in Focus; Announces India’s AI Super Highway Project! 

Indoco Remedies Share Price Performance 

As of October 27, 2026, 3:27 pm, Indoco Remedies share price was trading at ₹217.30, a 1.00% decrease from the previous closing price. 

Conclusion 

The board approved the unaudited standalone and consolidated results on 27 October 2026. Statutory auditors Gokhale & Sathe conducted a limited review of the financial statements and issued reports with unmodified conclusions. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.